Secukinumab Archives - Medical Conferences

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

Advanced therapies show promising results in PsA real-world study

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

PRO-SPIRIT

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:38

How close are we to personalised medicine in psoriatic arthritis?

Presented By

Prof. Ennio Lubrano, University of Molise, Ital

Conference

IFPA 2024

Type

News article

17 July 2024 14:38

The unfavourable role of obesity in psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Center Schleswig-Holstein, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:13

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

Hidradenitis suppurativa treatment with secukinumab linked to low immunogenicity

Presented By

Prof. Martina Porter, Beth Israel Deaconess Medical Center, USA

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:33

IV secukinumab safe and effective for long-term treatment of active PsA

Presented By

Prof. Iain McInnes, University of Glasgow, Scotland

Trial

FUTURE 2-5

Conference

ACR 2023

Type

News article

1 December 2023 12:04

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

Anti-IL17 blockade leads to maintained pain reduction in patients with HS

Presented By

Dr John Ingram, Cardiff University, UK

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:44

AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression

Presented By

Prof. Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Germany

Trial

Phase 3, SURPASS

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:22

High potential for secukinumab as next biologic treatment for HS

Presented By

Prof. Alexandra Kimball, Harvard Medical School, MA, USA

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:06

IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab

Trial

Phase 3, BE RADIANT

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:35

New treatments for HS: IL-17 inhibitors next in practice?

Presented By

Dr Axel Villani, University of Lyon, France & Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:05

How to treat enthesitis in 2022

Presented By

Prof. Dennis McGonagle, University of Leeds, United Kingdom

Trial

Phase 3, SEAM-PsA, EXCEED, SPIRIT-H2H

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:42

Dermatology diseases need the highest doses of biologics

Presented By

Dr Charlotte Greif, Beth Israel Deaconess Medical Center, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:24

Secukinumab also tolerable in paediatric psoriasis patients

Presented By

Prof. Michael Sticherling, University Erlangen–Nürnberg, Germany

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:22

Intermediate monocytes are possible predictors of response to secukinumab

Presented By

Dr Jonathan Hardman-Smart, King’s College London, UK

Trial

Phase 3, SIGNATURE

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:34

HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario

Presented By

Dr Oras Alabas, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:05

IL-17 inhibition showing efficacy in GCA in phase 2 trials

Presented By

Prof. Jens Thiel, Medical University Graz, Austria

Trial

Phase 2, TitAIN

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 11:05

Ixekizumab superior to secukinumab in real-world psoriasis study

Presented By

Dr Caterina Cariti, University of Turin, Italy

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:16

Psoriasis: New treatments and current pipeline

Presented By

Prof. Kristian Reich, Dermatologikum Hamburg, Germany

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:08

Efficacy and safety of secukinumab in juvenile idiopathic arthritis

Presented By

Dr Nicola Ruperto, IRCCS Istituto G. Gaslini, Italy

Trial

Phase 3, JUNIPERA

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:33

IL-17 inhibitor effective in axial manifestations of psoriatic arthritis

Trial

Phase 3, MAXIMISE

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

Bimekizumab superior to secukinumab in psoriasis

Presented By

Prof. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 3, BE RADIANT

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:47

Selective IL-23 blocker shows potential in psoriasis treatment

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3, OASIS-2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:44

Secukinumab monotherapy as efficient as adalimumab

Presented By

Prof. Iain McInnes, University of Glasgow, United Kingdom

Trial

Phase 3, EXCEED

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 13:11

ECLIPSE trial: skin clearance independent of PsA status at baseline

Presented By

Prof. Kristian Reich

Trial

Phase 3, ECLIPSE

Conference

AAD 2020

Type

Peer-reviewed article

7 August 2020 13:12

Biologics in HS – a growing armamentarium

Presented By

Prof. Joslyn Kirby, Penn State University, USA

Trial

PIONEER

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 12:48

Psoriasis therapy for children and pregnancies

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

CRIB, CADMUS, IXORA-PEDS

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 08:03

Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis

Presented By

Prof. Richard B. Warren

Trial

IMMerge

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:07

Lowest risk of infection after therapy with an IL-12/IL-23 blocker

Presented By

Dr Yinzhu Jin, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA

Trial

Cohort study

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:42

IL-17 blocker: effective and safe in patients with comorbidities

Presented By

Dr Alice Gottlieb, Tufts University School of Medicine, USA

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 20:19

Registries – an important research tool in biologics

Presented By

Prof. Bruce E. Strober, UConn Health, USA

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 10:10

Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?

Presented By

Prof. Kristian Reich, Georg-August-University Göttingen, Germany

Trial

ECLIPSE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 18:23

IBD risk of treatment with IL-17 antagonists

Presented By

Dr Wolfgang Eigner, Medical University of Vienna, Austria

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 14:37

Secukinumab maintains improvements in psoriasis through 5 years of treatment

Presented By

Prof. Richard Langley, Dalhousie University, Canada

Trial

ERASURE/FIXTURE

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 23:10

Psoriasis and Biologics: The Beat Goes On

Presented By

Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:06